Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments

Retina

Volumn 34, Issue 11, 2014, Pages 2161-2166

  Rusu, Irene ^a   Deobhakta, Avnish ^a,b,c,d   Yoon, Dan ^a   Lee, Michele ^c   Slakter, Jason ^b,e   Klancnik, James ^b,e   Thompson, Desmond ^f   Freund, K ^a,b,d,e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

^c College of Phys and Surg ^*  (United States)

^d New York Presbyterian Hospital   (United States)

^e EAR AND THROAT HOSPITAL   (United States)

^f REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

aflibercept; bevacizumab; intraocular pressure; neovascular age related macular degeneration; ranibizumab

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; STATISTICAL SIGNIFICANCE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG SUBSTITUTION; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84926467272     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000264     Document Type: Article

References (26)

1. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
2. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-1398.
3. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-1411.
4. Kodjikian L, Souied EH, Mimoun G, et al; GEFAL Study Group. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 2013;120:2300-2309.
5. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-2548.
6. Hollands H, Wong J, Bruen R, et al. Short-Term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-811.
7. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-Term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930-934.
8. Mojica G, Hariprasad SM, Jager RD, Mieler WF. Short-Term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration [letter]. Br J Ophthalmol 2008;92:584.
9. Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 2009;23:181-185.
10. Tseng J, Vance S, Della Torre K, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012;21:241-247.
11. Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti VEGF agents. Br J Ophthalmol 2011;95:1111-1114.
12. Bakri SJ, McCannel CA, Edwards AO, et al. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955-958.
13. Kahook My, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40:293-295.
14. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105-110.
15. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
16. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1432-1444.
17. Bakri SJ, Moshfeghi DM, Rundle A, et al. IOP in eyes treated with monthly ranibizumab: a post hoc analysis of data from the MARINA and ANCHOR trials. Paper presented at: The American Academy of Ophthalmology (AAO) Annual Meeting; October 17, 2010; Chicago, IL.
18. Hoang QV, Mendonca LS, Della Toree KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012;119:321-326.
19. Hoang QV; Freund KB on behalf of the VIEW 1 and VIEW 2 Study Investigators. Intraocular pressure in patients with neovascular AMD receiving intravitreal aflibercept or ranibizumab injection. Paper presented at: The American Academy of Ophthalmology (AAO) Annual Meeting; Fort Lauderdale, FL, May 6-9, 2012.
20. Heijl A, Leske MC, Bengtsson B, et al; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1268-1279.
21. Kocabora MS, Ozbilen KT, Serefoglu K. Intravitreal silicone oil droplets following pegaptanib injection. Acta Ophthalmol 2010;88:e44-e45.
22. Freund KB, Laud K, Eandi CM, et al. Silicone oil droplets following intravitreal injection. Retina 2006;26: 701-703.
23. Scott IU, Oden NL, VanVeldhuisen PC, et al. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs. luer cone syringe design. Am J Ophthalmol 2009;148:725-732.e7.
24. Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina 2008;28:996-1001.
25. Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93: 457-462.
26. Ladas JG, Yu F, Loo R, et al. Relationship between aqueous humor protein level and outflow facility in patients with uveitis. Invest Ophthalmol Vis Sci 2001;42:2584-2588.